Italian medical laboratory Gruppo Centro Servizi Medici (CSM) has installed the SOPHiA DDM Platform developed by software company SOPHiA GENETICS.
The SOPHiA DDM Platform is used by hospitals, laboratories and biopharmaceutical institutions worldwide to analyse complex multimodal data sets and different diagnostic modalities.
Go deeper with GlobalData
Using the cloud-native platform, CSM aims to expand its next-generation sequencing (NGS) capabilities and support its research into hereditary cancer and homologous recombination deficiency.
The laboratory intends to use the platform to improve the detection and categorisation of hereditary cancers, as well as help clinical researchers identify genomic profiles that respond effectively to specific therapies.
SOPHiA GENETICS managing director Kevin Puylaert said: “It is our goal to democratise data-driven medicine, and the enhanced testing offered by CSM will help enable that in Italy.
“By using the SOPHiA DDM Platform, CSM will have unified data across all access points, increasing the ease with which these sites can share data, communicate and deliver genomic analyses.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe platform uses artificial intelligence (AI) and patented technologies to examine and interpret NGS data.
According to SOPHiA GENETICS, it enables a more efficient bioinformatics workflow and will provide CSM with in-house ownership of genomic databases shared across its access points.
This is intended to translate into quicker data interpretation and expedited delivery of results.
CSM carries out more than one million exams a year, providing around 1,500 types of tests.
Last week, Centre Hospitalier de Bastia in Corsica began using SOPHiA GENETICS’ SOPHiA DDM Platform.
The platform is intended to allow the hospital to introduce in-house NGS and support its clinical oncology research, particularly in the field of haematologic malignancies.
Centre Hospitalier de Bastia’s work with SOPHiA DDM will focus on haematologic cancers such as leukaemia and lymphoma, as the platform could help categorise disease-associated mutations and provide deeper insights.
